Search results for: Multi-Indication Medicines
Filter search results
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…government and donor “push” funding of research, development, and manufacturing. Mechanisms which reward follow-on products rather than a ‘winner takes all’ approach. Multi-country patent buy-outs at a value-based price or…
Victor R. Fuchs Award for 2020 Goes to Patricia Danzon
23 June 2020
…found that in Middle and Low Income Countries (MLICs), generic prices were high despite competition, due to a lack of quality regulation. Tendering led to multinational generic suppliers entering markets…
OHE at HESG Winter 2021
11 January 2021
…Mortality dataset, the General and Personal Medical Services, the General Practice Patient Survey, the NHS payments to General Practices, the Quality and Outcome Framework data, the Index of Multiple Deprivation…
Does the New CBO Report Change Anything?
15 September 2021
…are made. Whilst the decision rules of individual investors are different, they all have a threshold of expected returns which is a multiple of their investment (the cost of development)…
OHE Thanks Trustees for Their Service
17 December 2021
…and Outcomes Research and Health Technology Assessment in which OHE is highly active. Much of OHE’s work is global in nature, and Lou brought a wealth of experience in multi-country…
The NICE Health Technology Evaluation Manual: A Fresh Perspective Needed?
16 March 2022
…multiple, potentially overlapping effects remains controversial. However, there are many societal effects which can already be incorporated into standard calculations of a cost-per-QALY, including effects on carers’ quality of life;…
Accounting for Preference Heterogeneity in Discrete Choice Experiments
4 May 2022
…J., Mestre-Ferrandiz, J., & Hopkins, M. M. (2020). A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. Applied Health Economics and Health Policy, 18(1), 69–79….
The State of Play for Cost-effectiveness Thresholds
28 June 2022
…the use of thresholds in practice, most notably the routine use of multiple thresholds or threshold ranges. The most substantial methodological challenge is to identify causal effects for the impact…
The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis
30 June 2022
…challenges and unresolved questions. In “Multi-Criteria Decision Analysis to Support Healthcare Decisions” Marsh, K., Goetghebeur, M., Thokala, P., Baltussen, R. (Eds.). Springer book. DOI Appraising Ultra-Orphan Drugs: Is Cost-per-QALY Appropriate?…